ArticleFrontiers in immunology2022

ACT001 Inhibits TLR4 Signaling by Targeting Co-Receptor MD2 and Attenuates Neuropathic Pain.

Tianshu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.